The article highlights Mereo BioPharma Group (MREO) as a potential growth stock capable of delivering significant returns, noting that its American depository shares have lost approximately 65% of their value since April 2019 due to market impatience with clinical-stage biotechs. The primary catalyst for Mereo is its anti-TIGIT therapy candidate, etigilimab, which is currently in a combined phase 1/2 basket study evaluating its utility in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo for various solid tumors. Top-line data from this trial is expected in approximately 18 months, but the company plans to provide multiple interim updates that could serve as major share price catalysts. Mereo maintains a cash runway extending into 2024, reducing the immediate need to raise capital, though management has expressed a desire to partner with larger biopharmaceutical firms, potentially leading to a high-dollar licensing agreement or buyout within two years. The main downside risk involves the high failure rate of early-stage cancer therapies in clinical trials, which could weigh heavily on the stock if etigilimab does not succeed. Senseonics Holdings (SENS) is presented as another aggressive growth opportunity centered on its implantable continuous glucose monitoring (CGM) device franchise, Eversense. The company aims to improve its competitive positioning against market leaders like DexCom and Abbott Laboratories by seeking FDA approval for an 180-day version of the Eversense CGM system, a regulatory application submitted over a year ago that could be decided soon. Senseonics projects that this approval would drive top-line growth at a compound annual rate of over 70% over the next five years, transforming the current 90-day device into a more competitive product in the U.S. market. While the CGM market has grown by over 10% annually for the past five years and is forecast to continue growing, Senseonics faces significant risks from competing against well-capitalized medical-device giants with superior resources, which could dampen sales even if regulatory approval is granted. The analysis concludes that both Mereo BioPharma Group and Senseonics Holdings represent low-priced healthcare stocks with the potential for 1,000%-plus returns within two to three years, provided their key development milestones are met. For Mereo, success hinges on the performance of etigilimab in combination with Bristol Myers Squibb's Opdivo and potential strategic partnerships, while investors are advised to keep positions small due to the binary nature of clinical trial outcomes. For Senseonics, the inflection point is the FDA decision on the longer-lasting Eversense device, which could unlock substantial growth if it successfully challenges established competitors like DexCom and Abbott Laboratories. Both companies are characterized as suitable for ultra-aggressive investors willing to tolerate high volatility in exchange for the possibility of a monstrous run higher driven by specific regulatory or clinical data events.